

1 **Full Title (85/250 characters)**

2 Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older

3

4 **Short Title (46/75 characters)**

5 Rapid cycle analysis of COVID-19 vaccines in Medicare

6

7 Hui-Lee Wong¹, Ellen Tworkoski², Cindy Ke Zhou¹, Mao Hu², Deborah Thompson¹, Bradley
8 Lufkin², Rose Do¹, Laurie Feinberg², Yoganand Chillarige², Rositsa Dimova¹, Patricia Lloyd¹,
9 Thomas MaCurdy^{2,3}, Richard A. Forshee¹, Jeffrey Kelman⁴, Azadeh Shoaibi¹, Steven A.
10 Anderson¹

11

12 **Author Affiliations:**

13 ¹US Food and Drug Administration, Silver Spring, MD

14 ²Acumen LLC, Burlingame, CA

15 ³Department of Economics, Stanford University, Stanford, CA, USA

16 ⁴Centers for Medicare & Medicaid Services, Washington, DC

17

18 **Corresponding Author:**

19 Steven A. Anderson, PhD

20 email: steven.anderson@fda.hhs.gov (SA)

21

22 **Conflict of Interest Statement**

23 All authors have completed the ICMJE uniform disclosure form at

24 www.icmje.org/coi_disclosure.pdf and declare: Hui-Lee Wong, Cindy Zhou, Deborah

25 Thompson, Rositsa Dimova, Patricia Lloyd, Richard Forshee, and Steven Anderson are/were

26 salaried employees of the U.S. Food and Drug Administration; Ellen Tworkoski, Mao Hu,

27 Bradley Lufkin, Rose Do, Laurie Feinberg, Yoganand Chillarige, and Thomas MaCurdy

28 are/were salaried employees of Acumen, LLC, which is a contractor with the U.S. Food and

29 Drug Administration; Jeffrey Kelman is a salaried employee of the Centers for Medicare &

30 Medicaid Services; Ellen Tworkoski is currently a salaried employee of Biogen, which includes
31 stock options provided to her as part of employee benefits; no other relationships or activities
32 that could appear to have influenced the submitted work.

33

34 **Abstract (294/300 words)**

35 **Background:** Monitoring safety outcomes following COVID-19 vaccination is critical for
36 understanding vaccine safety especially when used in key populations such as elderly persons
37 age 65 years and older who can benefit greatly from vaccination. We present new findings from
38 a nationally representative early warning system that may expand the safety knowledge base to
39 further public trust and inform decision making on vaccine safety by government agencies,
40 healthcare providers, interested stakeholders, and the public.

41
42 **Methods:** We evaluated 14 outcomes of interest following COVID-19 vaccination using the US
43 Centers for Medicare & Medicaid Services (CMS) data covering 30,712,101 elderly persons.
44 The CMS data from December 11, 2020 through Jan 15, 2022 included 17,411,342 COVID-19
45 vaccinees who received a total of 34,639,937 doses. We conducted weekly sequential testing and
46 generated rate ratios (RR) of observed outcome rates compared to historical (or expected) rates
47 prior to COVID-19 vaccination.

48
49 **Findings:** Four outcomes met the threshold for a statistical signal following Pfizer-BioNTech
50 vaccination including pulmonary embolism (PE; RR=1.54), acute myocardial infarction (AMI;
51 RR=1.42), disseminated intravascular coagulation (DIC; RR=1.91), and immune
52 thrombocytopenia (ITP; RR=1.44). After further evaluation, only the RR for PE still met the
53 statistical threshold for a signal; however, the RRs for AMI, DIC, and ITP no longer did. No
54 statistical signals were identified following vaccination with either the Moderna or Janssen
55 vaccines.

56

57 **Interpretation:** This early warning system is the first to identify temporal associations for PE,
58 AMI, DIC, and ITP following Pfizer-BioNTech vaccination in the elderly. Because an early
59 warning system does not prove that the vaccines cause these outcomes, more robust
60 epidemiologic studies with adjustment for confounding factors, including age and nursing home
61 residency, are underway to further evaluate these signals. FDA strongly believes the potential
62 benefits of COVID-19 vaccination outweigh the potential risks of COVID-19 infection.

63 **Introduction**

64 The US Food and Drug Administration (FDA) is monitoring the safety of three vaccines for
65 Coronavirus Disease 2019 (COVID-19) currently available in the US. These include the licensed
66 Pfizer BioNTech vaccine (Comirnaty) for persons 16 years and older and authorized under
67 emergency use authorization (EUA) for those 12-15 years (BNT162b2), as well as the authorized
68 Moderna (mRNA-1273), and Janssen (Ad26.COV2.S) vaccines for persons 18 years and older.
69 Pre-authorization clinical studies provided useful information on the safety of COVID-19
70 vaccines, but they have limitations such as sample size and follow-up that may be addressed in
71 post-authorization safety studies in large healthcare databases. Accordingly, FDA and the
72 Centers for Medicare & Medicaid Services (CMS) are using the Medicare health insurance
73 database, covering more than 25 million elderly persons aged 65 years and older, to conduct near
74 real-time safety monitoring of 14 outcomes on a weekly basis following COVID-19 vaccine
75 administration.

76 The US elderly population, including persons in Long-Term Care Facilities or nursing
77 homes [1], were disproportionately affected by COVID-19, as they were among the first US
78 populations to be infected. Because they suffered a higher rate of infection, serious disease, and
79 severe outcomes including death [2], they were among the first groups recommended by the
80 Advisory Committee on Immunization Practices to receive the vaccine [3]. Available
81 information concerning the safety of the vaccine in elderly persons is limited. However, the near
82 real-time surveillance method used by FDA and CMS continues to expand the available
83 knowledge base and further advances our understanding of the safety profile of these new
84 COVID-19 vaccines. The FDA-CMS near real-time active surveillance program complements
85 other FDA and US Government vaccine safety surveillance systems by rapidly detecting safety
86 concerns that may not have been voluntarily reported to passive surveillance systems such as

87 Vaccine Adverse Event Reporting System. Routinely used by FDA in safety surveillance for
88 annual influenza vaccines in the past decade, this method is designed to be sensitive enough to
89 quickly screen safety signals for further evaluation in robust epidemiologic studies [4, 5]. This
90 rapid screening method performs hypothesis testing, sequentially, in a prospective manner as the
91 vaccine data accrue to detect potential safety signals earlier in the course of surveillance, but
92 signals must be further evaluated in more robust studies with adjustment for confounding.
93 However, results detected by near real-time surveillance do not establish a causal association
94 between the outcomes and vaccination because the method has limited adjustments for
95 confounding.

96 In this report, we summarize the results of weekly sequential testing analyses for 14
97 outcomes where formal testing was initiated. We also describe how the identified signals were
98 evaluated and how the epidemiological studies currently underway will provide more robust
99 adjustment for confounding determine if any are true signals.

100

101 **Methods**

102 *Data Sources*

103 We used the US Medicare Fee-for-Service (FFS) Parts A (inpatient services) and B (outpatient
104 care) claims and enrollment data to define inclusion criteria, exposures, outcomes, and patient
105 characteristics. The number of 65+ beneficiaries with at least 1 day of Medicare FFS enrollment
106 in the study period is 30,712,101. The Minimum Data Set identified nursing home residency
107 status.

108 *Study Period and Population*

109 The study included Medicare FFS beneficiaries aged 65 years or older who received a COVID-
110 19 vaccine since December 11, 2020. To be included, individuals needed to be enrolled on the
111 vaccination date, and continuously enrolled during an outcome-specific pre-vaccination clean
112 window [6].

113 ***Exposure and Follow-Up***

114 Exposure was defined as receipt of a Pfizer-BioNTech, Moderna, or Janssen COVID-19
115 vaccination, identified using brand and dose-specific Current Procedural Terminology /
116 Healthcare Common Procedure Coding System codes [7] (Table S1). The primary analysis
117 included all observed doses by brand. Dose-specific analyses are described in supplemental
118 materials. Follow-up included all time in the prespecified risk windows; the first-dose risk
119 window was censored at the time of the second-dose vaccination.

120 ***Outcomes***

121 The list of 14 outcomes, pre-vaccination clean windows, and post-vaccination risk windows are
122 detailed in Table S2. Claims-based outcome algorithms were developed based on literature
123 review and in consultation with clinical experts [8].

124 ***Vaccine Safety Surveillance***

125 Weekly vaccine uptake was monitored by brand. The near real-time surveillance compared the
126 observed number of each outcome in the COVID-19 vaccinated population to an expected
127 number based on the background rate of the outcome in a similar COVID-19 unvaccinated
128 population prior to the pandemic, adjusted for the delay in claims processing and standardized by
129 nursing home residency status, age, sex, and race. We calculated annual background rates within
130 the strata of the standardized variables, where possible, during 2017-2019 (pre-COVID-19) and

131 peri-COVID-19 (January 1, 2020–December 10, 2020) [9] (Table S3). If annual rates in the
132 historical period differed substantially from each other, we selected the minimum rate as a more
133 conservative approach. Otherwise, the median annual rate was selected.

134 *Statistical Analysis*

135 Poisson Maximized Sequential Probability Ratio Test (PMaxSPRT) was used to detect increased
136 outcome risk following vaccination compared to a historical baseline for 14 outcomes [10-12]
137 (Table S3). Weekly sequential testing for each outcome commenced when a minimum of three
138 cases accrued. One-tailed tests were used, with a null hypothesis that the observed rate was no
139 greater than the historical comparator beyond a prespecified test margin with an overall alpha of
140 1%. The test margin was selected for each outcome based on expert guidance to avoid minimal
141 risk increases that were unlikely to be clinically relevant. The alpha level was selected to address
142 a large number of tests. A statistical signal occurred if the log likelihood ratio exceeded the
143 critical value, or a threshold for determining whether the result was likely to occur due to chance.
144 Additional details are provided in Table S3 and the study protocol [6].

145 *Signal Evaluation*

146 Prespecified signal evaluation analyses were conducted after a statistical signal was observed.
147 Data quality was checked to rule out database errors or changes in event observation as potential
148 sources of the signal. Sensitivity analyses evaluated whether the increase in risk was observed
149 with alternate expected rates in sequential testing – (i) rates from calendar months in the
150 historical period corresponding to those in the study period to address monthly variations in the
151 background rates, and (ii) rates among a subset of Medicare beneficiaries with influenza
152 vaccination in the past year to assess differential healthcare utilization. For pulmonary embolism

153 (PE), additional ad hoc analyses were conducted with (i) the outcome limited to the inpatient
154 setting and (ii) rates from November 1–December 11, 2020 to address changes in rates in the
155 peri-COVID period as alternate expected rates.

156 Signal characterization assessed the cases and the potential elevated risk. Analyses
157 included (i) identifying clusters in the risk window following dose 1 through temporal scans, (ii)
158 estimating relative risks within demographic strata, (iii) assessing distribution of care settings
159 and diagnosis codes in observation and historical periods, (iv) comparing patient characteristics
160 among vaccinated and overall elderly populations, and (v) reviewing patterns of reimbursement
161 codes by clinicians on a random sample of up to 100 cases per outcome to contextualize the
162 medical histories of patients.

163 *Statistical Software*

164 All analyses were conducted using R 4.0.3 (R Foundation for Statistical Computing, Vienna,
165 Austria), SAS v. 9.4 (SAS Institute Inc., Cary, NC, United States), and SaTScan v9.6 (Martin
166 Kulldorff, Boston, MA, United States).

167 *Ethical Considerations*

168 This surveillance activity was conducted as part of the FDA public health surveillance mandate.

169 **Results**

170 *Descriptive Statistics of the COVID-19 Vaccinated Population*

171 From December 11, 2020 through January 15, 2022, 17,088,796 Pfizer-BioNTech, 16,898,376
172 Moderna, and 634,019 Janssen COVID-19 vaccine doses were found among 30,712,101 eligible
173 individuals in the study period (34,621,191 total vaccine doses including vaccination days with
174 multiple products). The population of Pfizer-BioNTech vaccinees had a slightly higher

175 proportion of older individuals (85 years and older), nursing home residents, and individuals
176 residing in urban areas compared to the general elderly Medicare population (Table 1; Figure 1).
177 Moderna vaccinees exhibited similar characteristics to the general Medicare population, while
178 the population receiving the Janssen vaccine was younger and had fewer nursing home residents.

179 **Table 1: Characteristics of Pfizer-BioNTech, Moderna, and Janssen Vaccine Doses Administered among Adults Aged 65 years**
 180 **and Older in Medicare^a, Dec 11, 2020 to January 15, 2022**

Patient Characteristic	General 65+ FFS ^b	Moderna ^c	Pfizer	Janssen	SMD - Comparison with General FFS ^c		
					Moderna	Pfizer	Janssen
Total	25,390,578	15,761,718	15,896,042	576,698			
Nursing Home Residency Status							
Nursing Home Resident	578,908 (2.3)	324,991 (2.06)	711,437 (4.48)	12,948 (2.25)	0.02	0.12	0.00
Non-Nursing Home Resident	24,811,670 (97.7)	15,436,727 (97.94)	15,184,605 (95.52)	563,750 (97.75)	0.02	0.12	0.00
Age (years)							
65-74	13,661,915 (53.8)	8,333,648 (52.87)	8,080,719 (50.83)	347,687 (60.29)	0.02	0.06	0.13
75-84	8,288,448 (32.6)	5,369,646 (34.07)	5,383,100 (33.86)	166,011 (28.79)	0.03	0.03	0.08
85+	3,440,215 (13.5)	2,058,424 (13.06)	2,432,223 (15.30)	63,000 (10.92)	0.01	0.05	0.08
Sex							
Female	14,191,641 (55.9)	9,010,306 (57.17)	9,324,988 (58.66)	319,812 (55.46)	0.03	0.06	0.01
Male	11,198,935 (44.1)	6,751,412 (42.83)	6,571,054 (41.34)	256,886 (44.54)	0.03	0.06	0.01
Race/Ethnicity							
Asian	529,362 (2.1)	320,757 (2.04)	341,530 (2.15)	10,113 (1.75)	0.00	0.00	0.03
Black	1,728,808 (6.8)	764,033 (4.85)	898,467 (5.65)	33,219 (5.76)	0.08	0.05	0.04
Hispanic	398,426 (1.6)	146,371 (0.93)	162,556 (1.02)	6,578 (1.14)	0.06	0.05	0.04
Alaskan Native/Native American	117,539 (0.5)	64,557 (0.41)	67,878 (0.43)	1,421 (0.25)	0.01	0.01	0.04
White	21,584,886 (85.0)	13,776,628 (87.41)	13,714,047 (86.27)	504,406 (87.46)	0.07	0.04	0.07
Other	448,630 (1.8)	282,212 (1.79)	299,951 (1.89)	7,555 (1.31)	0.00	0.01	0.04
Missing/Unknown	582,927 (2.3)	407,160 (2.58)	411,613 (2.59)	13,406 (2.32)	0.02	0.02	0.00
Urban/Rural							
Urban	19,415,683 (76.5)	11,855,600 (75.22)	1,346,1164 (84.68)	436,146 (75.63)	0.03	0.21	0.02
Rural	5,811,513 (22.9)	3,822,143 (24.25)	2,359,912 (14.85)	138,341 (23.99)	0.03	0.21	0.03
Missing/Unknown	163,382 (0.6)	83,975 (0.53)	74,966 (0.47)	2,211 (0.38)	0.01	0.02	0.03


181 Abbreviations: FFS, Fee-for-Service; SMD, standardized mean difference; AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019

182 ^a Individuals included in this table were required to have 365 days of continuous enrollment prior to vaccination date in order to accurately capture medical history. Therefore, the total vaccine doses for
 183 this subpopulation is smaller than the study population of Medicare FFS 65+ study population reported in the Results section.

184 ^b Characteristics of the general Medicare FFS population aged 65 years and older were assessed as of 12/10/2020

185 ^c SMD with values greater than 0.1 are presented in bold text and indicate covariates with larger imbalances between populations

186 **Fig 1. Cumulative COVID-19 Vaccine Doses, by Age and Sex, in Adults Aged 65 Years and**
 187 **Older in the Medicare Shared Systems Data, by Vaccine Brand, Dec 11, 2020 to January**
 188 **15, 2022**



189
 190 Comparing data cuts through April 24, 2021 (Table S6), March 13, 2021 (Table S7) and
 191 February 27, 2021 (Table S8), the populations differed for those who were vaccinated from mid
 192 December 2020 to February 2021 versus the later months. Pfizer vaccinees experienced more
 193 hospitalizations in the prior year and higher proportions of underlying medical conditions (e.g.,
 194 Charlson comorbidity index > 0), when compared to the overall elderly Medicare, Moderna, or
 195 Janssen populations.

196 ***PMaxSPRT Sequential Testing Results***

197 All outcomes with primary analyses for PMaxSPRT testing met the prespecified criteria for
 198 initiation of analyses (Table S3). No statistical signals were identified following vaccination with

199 either the Moderna or Janssen vaccines. AMI (RR=1.42), PE (RR=1.54), disseminated
200 intravascular coagulation (DIC; RR=1.91), and immune thrombocytopenia (ITP; RR=1.44)
201 following Pfizer-BioNTech vaccination met the statistical threshold for a signal (Table 2). Dose-
202 specific results can be seen in Tables S4-5.

203
204

Table 2: Summary of Sequential Testing Results in Adults Aged 65 years and Older in the Medicare Shared Systems Database for Any Dose by Vaccine Brand, Dec 11, 2020 to January 15, 2022

Outcomes, by Vaccine Brand	Vaccine Brand	Observed Person Time (Days)	Number of Doses	Number of Observed Outcomes (as of 01/15/2022) ^a	Relative Risk of Observed vs. Expected (Any Dose; 01/15/2022) ^b	Signal Identified ^c
Acute Myocardial Infarction	Pfizer-BioNTech	402,380,589	15,747,074	13,293	0.97	Yes - 2/27/2021 (RR=1.42)
	Moderna	423,244,936	15,628,229	12,909	0.94	No
	Janssen	13,156,815	570,434	548	1.30	No
Deep Vein Thrombosis	Pfizer-BioNTech	402,057,021	15,600,926	12,871	0.88	No
	Moderna	424,775,904	15,507,286	11,342	0.78	No
	Janssen	13,126,819	567,190	480	1.07	No
Pulmonary Embolism	Pfizer-BioNTech	404,173,653	15,684,098	9,443	1.15	Yes – 2/27/2021 (RR=1.54)
	Moderna	426,520,976	15,571,477	8,996	1.08	No
	Janssen	13,184,317	569,676	346	1.34	No
Disseminated Intravascular Coagulation	Pfizer-BioNTech	405,993,894	15,891,008	355	0.92	Yes – 3/13/2021 (RR=1.91)
	Moderna	426,696,226	15,757,044	303	0.80	No
	Janssen	13,297,825	576,495	14	1.11	No
Non-hemorrhagic Stroke	Pfizer-BioNTech	403,683,932	15,799,026	7,882	0.85	No
	Moderna	424,648,679	15,680,668	7,646	0.83	No
	Janssen	13,214,072	572,972	297	1.06	No
Hemorrhagic Stroke	Pfizer-BioNTech	405,580,548	15,874,528	2,128	0.96	No
	Moderna	426,350,816	15,744,161	1,958	0.88	No
	Janssen	13,283,534	575,871	77	1.12	No
Immune Thrombocytopenia	Pfizer-BioNTech	554,443,925	15,857,949	1,670	1.26	Yes – 4/24/2021 (RR=1.44)
	Moderna	573,697,153	15,725,918	1,526	1.14	No
	Janssen	19,848,219	575,565	62	1.34	No
Myocarditis/Pericarditis	Pfizer-BioNTech	555,100,577	15,876,623	1,415	1.10	No
	Moderna	574,346,394	15,743,573	1,259	0.97	No
	Janssen	19,865,485	576,075	48	1.04	No
Guillain-Barre Syndrome	Pfizer-BioNTech	532,555,069	15,892,318	69	1.14	No
	Moderna	536,703,703	15,758,009	53	0.86	No
	Janssen	19,582,979	576,548	**	3.85	No
Bell’s Palsy	Pfizer-BioNTech	575,124,693	16,453,363	3,618	1.12	No
	Moderna	594,439,852	16,299,826	3,505	1.07	No
	Janssen	20,810,662	603,113	133	1.13	No
Encephalomyelitis/Encephalitis	Pfizer-BioNTech	561,415,207	16,479,530	153	1.21	No
	Moderna	572,296,487	16,324,225	120	0.98	No
	Janssen	20,648,928	604,024	**	1.68	No
Transverse Myelitis	Pfizer-BioNTech	541,656,398	15,892,229	66	1.36	No
	Moderna	552,699,497	15,757,865	48	1.00	No

Outcomes, by Vaccine Brand	Vaccine Brand	Observed Person Time (Days)	Number of Doses	Number of Observed Outcomes (as of 01/15/2022) ^a	Relative Risk of Observed vs. Expected (Any Dose; 01/15/2022) ^b	Signal Identified ^c
	Janssen	19,700,796	576,539	**	1.10	No
Narcolepsy	Pfizer-BioNTech	555,189,780	15,879,173	623	1.15	No
	Moderna	574,433,145	15,745,902	537	0.98	No
	Janssen	19,864,965	576,089	23	1.15	No
Appendicitis	Pfizer-BioNTech	548,982,786	15,880,177	1,180	1.06	No
	Moderna	564,851,514	15,745,889	1,190	1.04	No
	Janssen	19,785,242	576,111	37	0.86	No

^a ** indicates small cell size counts with fewer than 11.

^b The relative risk incorporates adjustments for observation delay as well as standardization by nursing home residency, sex, age, and race when indicated by in Table 3.

205
206

207 **Signal Evaluation**

208 None of the prespecified data quality assurance checks, including claims duplication and unusual
 209 variability in claim accrual, raised data quality concerns (Table S9). Primary findings for signal
 210 robustness and signal characterization analyses are summarized in Table 3. Adjustment for
 211 monthly variation in the background rates resulted in statistically non-significant associations for
 212 AMI, DIC, and ITP following Pfizer-BioNTech vaccination. With background rates from the flu-
 213 vaccinated population as the historical comparator, DIC and ITP no longer met the signal
 214 threshold, while signals for AMI (RR=1.41) and PE (RR=1.48) remained. When rates during the
 215 peri-COVID period were used as the historical comparator, PE and DIC no longer met the signal
 216 threshold. We conducted an additional ad hoc sensitivity analysis for PE. When PE events were
 217 restricted to the inpatient setting, the statistical signal remained (RR=2.17).

218 **Table 3: Summary of Characterization of Associations for Acute Myocardial Infarction,**
 219 **Pulmonary Embolism, Disseminated Intravascular Coagulation, and Immune**
 220 **Thrombocytopenia identified via Diagnosis Codes after Pfizer-BioNTech vaccination in**
 221 **Medicare Shared Systems Database**

Type of Evaluation	Evaluation Conducted	Summary of Findings	Interpretation
Signal Robustness	PMaxSPRT with secular trends adjustment	RR no longer statistically significant for AMI, DIC, and ITP. RR reduced but remained statistically significant for PE	Potential confounding for AMI, DIC, and ITP
	PMaxSPRT with expected rates from influenza vaccinated population	RR no longer statistically significant for DIC and ITP. RR remained statistically significant for AMI and PE	Potential confounding for DIC and ITP
	PMaxSPRT with expected rates from peri-COVID-19 time, for PE, DIC, and ITP	RR no longer statistically significant for PE and DIC. RR increased and remained statistically significant for ITP	Potential confounding for PE, DIC
	PMaxSPRT with cases in the inpatient setting only, for PE outcome only	RR increased and remained statistically significant for PE	PE signal robust to inpatient-only definition
Signal Characterization	Summarized covariate distributions of vaccinated individuals compared to the	Pfizer vaccinated individuals had a higher proportion of nursing home residents and older individuals than the general elder	Potential confounding specific to the Pfizer vaccinated population

Type of Evaluation	Evaluation Conducted	Summary of Findings	Interpretation
	general Medicare FFS population aged 65+	population throughout the study period. This was not seen for Moderna or Janssen	
	Reviewed profiles of diagnoses and procedures on claims one year prior to and following case date for 100 sampled cases with clinical experts	Outcome-specific risk factors seen for 41-96% of sampled cases, depending on outcome. Outcome-specific treatments or diagnostics only observed for 18-53% of sampled cases, depending on outcome	Requires further investigation
	Summarized frequency of individual codes and claim settings used to flag outcomes in the historical and observation periods	No differences between periods observed for DIC or ITP. A higher proportion of Type II AMI codes and non-primary inpatient diagnoses was observed in the observation period compared to the historical period for AMI. A higher proportion of subsegmental PE codes was observed in the observation period. Additionally, PE case counts in Nov and Dec 2020 were 20–40% higher than in historical period (i.e., 2019)	Requires further investigation
	Summarized frequency of prior COVID-19 diagnosis	Rates of prior COVID-19 diagnoses were higher among Pfizer vaccinated individuals than the general population. Rates of prior COVID-19 diagnoses were higher among individuals with an AESI than among all vaccinated individuals.	Yes, for all outcomes for which COVID-19 is a risk factor
	Performed temporal scans to identify clusters of cases post-vaccination	No statistically significant cluster for PE, ITP, or DIC. Statistically significant cluster identified from 1–17 days post Pfizer first dose for AMI	No specific narrow clusters of high risk identified for AMI, DIC, PE, or ITP
	Characterized relative risks by patient strata (nursing home residency status, sex, age, race, comorbidities status)	Larger RR in the nursing home residents compared to the non-nursing home residents for AMI (1.53 vs. 1.34), PE (1.66 vs. 1.47), and DIC (2.72 vs. 1.28). Larger RR in males compared to females for ITP (1.68 vs. 1.28).	For AMI, PE, and DIC elevated risk may be concentrated in the nursing home population

222

223 Clinical subject matter experts reviewed claims-based diagnoses and procedures for
 224 selected patients from one year prior through one year after the dates of sampled outcome events.
 225 They found outcome-specific comorbidities were present in 41%, 45%, 95%, and 66% of AMI,
 226 PE, DIC, and ITP cases, respectively. Additionally, only a single diagnosis without other


227 mention of the outcome occurred in 26%, 37%, 61%, and 49% of cases for AMI, PE, DIC, and
228 ITP, respectively. Outcome-specific treatments or diagnostics were observed in 34%, 53%, 40%,
229 and 18% of AMI, PE, DIC, and ITP cases, respectively.

230 Evaluation of claims-based diagnosis codes showed differences in coding patterns for
231 AMI and PE between the study period and the historical period used to calculate expected rates
232 (Table 3). Type II AMI codes, which are indicative of a mismatch between myocardial oxygen
233 supply and demand (as opposed to acute coronary thrombosis), were more common in outcomes
234 identified during the study period (46%) than in the historical period (28%). Additionally, for
235 both AMI and PE outcomes, a higher proportion of inpatient claims-based codes occurred in a
236 non-primary diagnosis position in the study period. No differences in coding patterns between
237 the study period and historical period were noted for either ITP or DIC.

238 Finally, temporal scans conducted at the time of signal did not identify any clustering of
239 cases within the post-vaccination risk window for PE, DIC, or ITP post Pfizer's first dose. A
240 scan for clusters 1-18 days long identified a statistically significant cluster of 1-17 days for AMI;
241 however, the observed rate of events in the cluster was only 4% higher than if events had been
242 evenly distributed in the risk window (Figure 2). Another scan for clusters 1-10 days long that
243 also accounted for censoring due to end of follow-up did not identify a statistically significant
244 cluster for AMI (Figure 2).

245

246 **Fig 2. Distribution of Days to Diagnosis of Acute Myocardial Infarction, Pulmonary**
247 **Embolism, Disseminated Intravascular Coagulation, or Immune Thrombocytopenia in 20**
248 **days after Pfizer-BioNTech Vaccination (First Dose) in Adults Aged 65 Years and Older,**
249 **the Medicare Shared Systems Database**



250

251 Discussion

252 Our early warning safety system is the first to identify four new statistical signals for modestly
253 elevated risks ($RR < 2$) of four serious outcomes of AMI, PE, DIC, and ITP following Pfizer-
254 BioNTech vaccination. This FDA and CMS COVID-19 vaccine safety study is one of the largest
255 studies of elderly persons aged 65 years and above including approximately 34 million doses
256 administered to more than 17 million Medicare insured persons. Our surveillance monitoring did
257 not detect statistical signals for the Moderna and Janssen vaccines for any of the 14 monitored
258 outcomes.

259 The statistical signals of four serious outcomes are not necessarily causal and may be due
260 to factors potentially unrelated to vaccination. Additional analyses indicated that the potential

261 association was less than twice the historical rates and may be associated with factors not
262 accounted for in the near real-time surveillance methods. For example, the elderly Medicare
263 population that received the Pfizer-BioNTech vaccine differed from other elderly COVID-19
264 vaccinated populations, including a preponderance of nursing home residents and populations
265 with a higher comorbidity burden. These demographic and medical differences were not fully
266 accounted for, since expected rates were only standardized to a subset of characteristics – age,
267 sex, race, and nursing home residency status. Further, the AMI, DIC, and ITP signals were not
268 robust when additional baseline rates were evaluated, while the PE signal might be explained by
269 differences in rates between the pre-COVID-19 and peri-COVID-19 periods. In addition, the
270 clinical assessment of patterns of reimbursement codes indicated that a substantial fraction had
271 pre-existing outcome-specific comorbidities and risk factors, and that some outcomes may be
272 due to follow-up care to an existing condition preceding the vaccination.

273 Our study has several strengths. This is the largest study of a population of more than 25
274 million elderly persons who are vulnerable to COVID-19 infections and complications-
275 including residents of long-term care facilities. By using the large Medicare nationwide database
276 with longitudinal linkage of vaccination, health services, and demographic information for
277 millions of elderly persons, we can detect even small increases in the relative risk of rare
278 outcomes for multiple vaccines that may not be captured in pre-authorization clinical trials. In
279 addition, this near real-time surveillance benefits from the experience and knowledge obtained
280 during more than a dozen years of successful collaboration between FDA and CMS conducting
281 vaccine safety analyses using the Medicare database [13], including near real-time surveillance
282 analyses for Guillain-Barré syndrome after influenza vaccination [14-16]. Furthermore, the
283 weekly data updates and analyses allow for signal detection across 14 outcomes using near-real

284 time monitoring. This further expands our knowledge of COVID-19 vaccine safety for informing
285 timely regulatory action, if warranted as well as decision-making by healthcare providers,
286 patients and the general public

287 We acknowledge our analysis has limitations. The near real-time analysis did not adjust
288 for underlying risk factors such as comorbidities among recipients in the early vaccination
289 campaign leading to falsely positive or negative signals. Furthermore, the early warning system
290 may falsely identify a signal (false positive) or signals because of the high number of statistical
291 tests performed or possible misspecification of parameters. Conversely, true safety signals (false
292 negatives) may be missed due to misspecified parameters in the analyses. Diagnosis billing codes
293 in claims data may underestimate or overestimate certain clinical conditions because of
294 reimbursement priorities. We also note that results of this near real-time surveillance in elderly
295 persons may not be generalizable to those younger than 65 years and adults who are uninsured or
296 received only commercial health insurance. To address several of these limitations we are
297 conducting further epidemiological studies along with medical record review to adjudicate
298 outcomes identified by claims-based definitions.

299 In conclusion, we demonstrate that this FDA-CMS early warning safety system is
300 working to rapidly identify potential new and important safety concerns following COVID-19
301 vaccination for consideration and to support potential decision-making by regulatory and public
302 health authorities, healthcare professionals and the general public. Our new findings of statistical
303 signals for four important outcomes for the Pfizer-BioNTech vaccine should be interpreted
304 cautiously because the early warning system does not prove that vaccines cause the safety
305 outcomes. FDA strongly believes the potential benefits of COVID-19 vaccination outweigh the
306 potential risks of COVID-19 infection. Per FDA communication of these findings, FDA is

307 currently not taking any regulatory actions based on these signal detection activities because
308 these signals are still under investigation and require more robust study. The FDA active
309 surveillance systems, including the CMS partnership, are a major part of a larger US federal
310 surveillance effort to increase knowledge of COVID-19 vaccine safety to support decision-
311 making that further protects public health during the pandemic.

312 **Acknowledgements**

313 We thank Joyce Obidi, PhD, Kristin “Kristine” Sepúlveda, MBA and Tainya Clarke, PhD, MPH,
314 MSc for program management and J. Rosser Matthews, PhD, MPP, MPH for writing support.
315 We would like to acknowledge John Hornberger, MD, MS, Nirmal Choradia, MD, Marna
316 Bogan, RN, CPC, Susan Siford, PharmD, MBA, Christina Jessee, RN, CPC for their clinical and
317 coding expertise. Additionally, we acknowledge Anchi Lo, MS, MPH, Jing Wang, BA, Yue Wu,
318 MS, Zhiruo Wan, MSE, Shanlai Shanguan, MPH, Rowan McEvoy, BS, Arnstein Lindaas, MA,
319 and Chianti Shi, MS for providing statistical programming support, and Yixin Jiao, MPP, Manzi
320 Ngaiza, MPH, and Ellie Smith, BS for providing writing support. We acknowledge Michael
321 Sklar, PhD, Lorene Nelson, PhD, MS, Julia Simard, ScD, SM, and Steve Goodman, MD, MHS,
322 PhD for their epidemiologic expertise. Finally, we acknowledge Ivair Silva, PhD for his
323 methodological expertise and development of the ‘Sequential’ R package used to conduct
324 analyses in this manuscript.

325 **References**

- 326 [1] Izurieta HS, Graham DJ, Jiao Y, Hu M, Lu Y, Wu Y, et al. Natural History of Coronavirus Disease 2019:
327 Risk Factors for Hospitalizations and Deaths Among >26 Million US Medicare Beneficiaries. *J Infect Dis.*
328 2021;223:945-56.
- 329 [2] US Department of Health and Human Services Office of Inspector General. COVID-19 Had a
330 Devastating Impact on Medicare Beneficiaries in Nursing Homes During 2020
- 331 [3] Dooling K, Marin M, Megan; W, McClung N, Chamberland M, Lee GM, et al. The Advisory Committee
332 on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine —
333 United States, December 2020. *MMWR Morb Mortal Wkly Rep* 2021;69:1657-1660. DOI:
334 <http://dx.doi.org/10.15585/mmwr.mm695152e22020>.
- 335 [4] Lee GM, Greene SK, Weintraub ES, Baggs J, Kulldorff M, Fireman BH, et al. H1N1 and seasonal
336 influenza vaccine safety in the vaccine safety datalink project. *Am J Prev Med.* 2011;41:121-8.
- 337 [5] Arya DP, Said MA, Izurieta HS, Perez-Vilar S, Zinderman C, Wernecke M, et al. Surveillance for
338 Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare
339 beneficiaries. *Vaccine.* 2019;37:6543-9.
- 340 [6] Wong H-L, Zhou CK, Thompson D, Dimova R, Clarke T, Forshee R, et al. COVID-19 Vaccine Safety
341 Surveillance: Active Monitoring Master Protocol. 2021.
- 342 [7] The American Medical Association. Appendix Q: Severe Acute Respiratory Syndrome Coronavirus 2
343 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines. 2021.
- 344 [8] U.S. Food and Drug Administration. Background Rates of Adverse Events of Special Interest for
345 COVID-19 Vaccine Safety Monitoring, Supplemental Table. 2021.
- 346 [9] Zhou CK, Wong H-L, Thompson D, Dimova R, Clarke T, Forshee R, et al. Background Rates of Adverse
347 Events of Special Interest for COVID-19 Vaccine Safety Monitoring. 2021.
- 348 [10] Belongia EA, Irving SA, Shui IM, Kulldorff M, Lewis E, Yin R, et al. Real-time surveillance to assess risk
349 of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. *Pediatr*
350 *Infect Dis J.* 2010;29:1-5.
- 351 [11] Kulldorff M, Davis RL, Kolczak† M, Lewis E, Lieu T, Platt R. A Maximized Sequential Probability Ratio
352 Test for Drug and Vaccine Safety Surveillance. *Sequential Analysis.* 2011;30:58-78.
- 353 [12] Yih WK, Nordin JD, Kulldorff M, Lewis E, Lieu TA, Shi P, et al. An assessment of the safety of
354 adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for
355 adverse events in the Vaccine Safety Datalink. *Vaccine.* 2009;27:4257-62.
- 356 [13] Burwen DR, Sandhu SK, MaCurdy TE, Kelman JA, Gibbs JM, Garcia B, et al. Surveillance for Guillain-
357 Barre syndrome after influenza vaccination among the Medicare population, 2009-2010. *Am J Public*
358 *Health.* 2012;102:1921-7.
- 359 [14] Sandhu SK, Hua W, MaCurdy TE, Franks RL, Avagyan A, Kelman J, et al. Near real-time surveillance
360 for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2010/11 to
361 2013/14. *Vaccine.* 2017;35:2986-92.
- 362 [15] Arya DP, Said MA, Izurieta HS, Perez-Vilar S, Zinderman C, Wernecke M, et al. Surveillance for
363 Guillain-Barre syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare
364 beneficiaries. *Vaccine.* 2019;37:6543-9.
- 365 [16] Perez-Vilar S, Wernecke M, Arya D, Lo AC, Lufkin B, Hu M, et al. Surveillance for Guillain-Barre
366 syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017-2018 season.
367 *Vaccine.* 2019;37:3856-65.
368

Population Labels \diamond 65-74 ∇ 75-84 \boxtimes 85+ \oplus Female \triangle Male $+$ Non-Nursing Home \times Nursing Home

